U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H37N5O9
Molecular Weight 467.5145
Optical Activity UNSPECIFIED
Defined Stereocenters 14 / 14
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TOBRAMYCIN

SMILES

[H][C@]3(O[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O[C@@]2([H])O[C@H](CO)[C@@H](O)[C@H](N)[C@H]2O)[C@H]1O)O[C@H](CN)[C@@H](O)C[C@H]3N

InChI

InChIKey=NLVFBUXFDBBNBW-PBSUHMDJSA-N
InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1

HIDE SMILES / InChI

Molecular Formula C18H37N5O9
Molecular Weight 467.5145
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 14 / 14
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several resourses, including http://www.drugbank.ca/drugs/DB00684

Tobramycin, an aminoglycoside antibiotic obtained from cultures of Streptomyces tenebrarius, it is effective against gram-negative bacteria, especially the pseudomonas species. Tobramycin is used in combination with other antibiotics to treat urinary tract infections, gynecologic infections, peritonitis, endocarditis, pneumonia, bacteremia and sepsis, respiratory infections including those associated with cystic fibrosis, osteomyelitis, and diabetic foot and other soft-tissue infections. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death. Tobramycin has in vitro activity against a wide range of gram-negative organisms including Pseudomonas aeruginosa. Tobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intracellular concentration of tobramycin. KITABIS PAK (co-packaging of tobramycin inhalation solution and PARI LC PLUS Reusable Nebulizer) is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with P. aeruginosa.

CNS Activity

Curator's Comment: Poor penetrability of tobramycin through the blood-CSF barrier was shown.

Originator

Curator's Comment: Tobramycin is the generic ingredient in eleven branded drugs marketed by Amneal Pharms, Chiesi Usa Inc, Akorn Inc, Fera Pharms, Pulmoflow Inc, Alcon, Alcon Labs Inc, Bausch And Lomb, Novartis Pharms, Alcon Pharms Ltd, Apotex Inc, Novartis, Teva Pharms Usa, Akorn, Lilly, Mylan Labs Ltd, Hospira, Hikma Maple , X Gen Pharms, Igi Labs Inc, Fresenius Kabi Usa, Apothecon, Watson Labs Inc, and Xellia Pharms Aps, and is included in forty-five NDAs. Nebramycin, an antibiotic complex of at least seven factors, was first described in 1967 by Stark et al.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
9.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
TOBREX

Approved Use

external infections of the eye

Launch Date

1980
Primary
KITABIS PAK

Approved Use

cystic fibrosis

Launch Date

2014
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.7 μg/mL
80 mg single, intramuscular
dose: 80 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
TOBRAMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
814 μg/mL
300 mg single, respiratory
dose: 300 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
TOBRAMYCIN unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
11.6 μg × h/mL
80 mg single, intramuscular
dose: 80 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
TOBRAMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.6 h
80 mg single, intramuscular
dose: 80 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
TOBRAMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.4 h
300 mg single, respiratory
dose: 300 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
TOBRAMYCIN unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
100%
300 mg single, respiratory
dose: 300 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
TOBRAMYCIN unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
12 mg/kg 1 times / day multiple, intravenous (mean)
Highest studied dose
Dose: 12 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg/kg, 1 times / day
Sources:
unhealthy, 2 months - 27 years
Health Status: unhealthy
Condition: cystic fibrosis
Age Group: 2 months - 27 years
Sources:
300 mg 2 times / day multiple, respiratory
Recommended
Dose: 300 mg, 2 times / day
Route: respiratory
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, >6 years
n = 190
Health Status: unhealthy
Age Group: >6 years
Sex: M+F
Population Size: 190
Sources:
Other AEs: Forced expiratory volume decreased, Rales...
Other AEs:
Forced expiratory volume decreased (31%)
Rales (19%)
Red blood cell sedimentation rate increased (8%)
Dysphonia (6%)
Wheezing (5%)
Sources:
3 mg 3 times / day multiple, ophthalmic
Recommended
Dose: 3 mg, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
unhealthy, adult
Other AEs: Hypersensitivity, Eyelids itchy sensation of...
Other AEs:
Hypersensitivity
Eyelids itchy sensation of
Swelling
Redness of eyelid conjunctiva
Sources:
1.5 mg/kg 3 times / day multiple, intramuscular
Dose: 1.5 mg/kg, 3 times / day
Route: intramuscular
Route: multiple
Dose: 1.5 mg/kg, 3 times / day
Sources:
unhealthy, adult
n = 28
Health Status: unhealthy
Condition: gram-negative bacilli infection
Age Group: adult
Population Size: 28
Sources:
2 mg/kg single, intraperitoneal
Dose: 2 mg/kg
Route: intraperitoneal
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, adult
n = 5
Health Status: unhealthy
Condition: end stage renal disease
Age Group: adult
Population Size: 5
Sources:
AEs

AEs

AESignificanceDosePopulation
Rales 19%
300 mg 2 times / day multiple, respiratory
Recommended
Dose: 300 mg, 2 times / day
Route: respiratory
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, >6 years
n = 190
Health Status: unhealthy
Age Group: >6 years
Sex: M+F
Population Size: 190
Sources:
Forced expiratory volume decreased 31%
300 mg 2 times / day multiple, respiratory
Recommended
Dose: 300 mg, 2 times / day
Route: respiratory
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, >6 years
n = 190
Health Status: unhealthy
Age Group: >6 years
Sex: M+F
Population Size: 190
Sources:
Wheezing 5%
300 mg 2 times / day multiple, respiratory
Recommended
Dose: 300 mg, 2 times / day
Route: respiratory
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, >6 years
n = 190
Health Status: unhealthy
Age Group: >6 years
Sex: M+F
Population Size: 190
Sources:
Dysphonia 6%
300 mg 2 times / day multiple, respiratory
Recommended
Dose: 300 mg, 2 times / day
Route: respiratory
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, >6 years
n = 190
Health Status: unhealthy
Age Group: >6 years
Sex: M+F
Population Size: 190
Sources:
Red blood cell sedimentation rate increased 8%
300 mg 2 times / day multiple, respiratory
Recommended
Dose: 300 mg, 2 times / day
Route: respiratory
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, >6 years
n = 190
Health Status: unhealthy
Age Group: >6 years
Sex: M+F
Population Size: 190
Sources:
Eyelids itchy sensation of
3 mg 3 times / day multiple, ophthalmic
Recommended
Dose: 3 mg, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
unhealthy, adult
Hypersensitivity
3 mg 3 times / day multiple, ophthalmic
Recommended
Dose: 3 mg, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
unhealthy, adult
Redness of eyelid conjunctiva
3 mg 3 times / day multiple, ophthalmic
Recommended
Dose: 3 mg, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
unhealthy, adult
Swelling
3 mg 3 times / day multiple, ophthalmic
Recommended
Dose: 3 mg, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
unhealthy, adult
PubMed

PubMed

TitleDatePubMed
Outbreak caused by tobramycin-resistant Pseudomonas aeruginosa in a bone marrow transplantation unit.
2001
Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs.
2001 Apr
[Mupirocin resistant MRSA in Japan].
2001 Apr
Effect of size and disease on estimated deposition of drugs administered using jet nebulization in children with cystic fibrosis.
2001 Apr
The role of nebulized antibiotics in treating serious respiratory infections.
2001 Aug
Crystal structure of paromomycin docked into the eubacterial ribosomal decoding A site.
2001 Aug
Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients.
2001 Aug
Mycobacterium keratitis following hyperopic laser in situ keratomileusis.
2001 Aug
Prevalence and analysis of risk factors for infections caused by resistant Escherichia coli strains in Anhui, China.
2001 Aug
In vitro elution of tobramycin from bioabsorbable polycaprolactone beads.
2001 Aug
Serratia Marcescens corneal ulcer as a complication of orthokeratology.
2001 Aug
Selective decontamination of the digestive tract in severely burned pediatric patients.
2001 Aug
[Adverse effects of transrectal prostatic biopsy. Analysis of 303 procedures].
2001 Jan
Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia.
2001 Jan-Feb
[Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1999)].
2001 Jul
Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies.
2001 Jul
Antibiotic therapy in intra-abdominal infections--a review on randomised clinical trials.
2001 Jul 30
Tobramycin (Cystic Fibrosis Foundation/PathoGenesis).
2001 Jun
Changing antibiotic sensitivity patterns at a university hospital, 1992 through 1999.
2001 Jun
Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia.
2001 Jun
Ultraviolet recall-like phenomenon occurring after piperacillin, tobramycin, and ciprofloxacin therapy.
2001 Jun
Population kinetics of tobramycin in neonates.
2001 Jun
In vitro selection of RNA against kanamycin B.
2001 Jun 30
Effect of some fractions of alveolar surfactant (phospholipids and SP-A) on the bactericidal activity of different antimicrobials against some respiratory pathogens.
2001 Mar
Aminoglycoside ototoxicity.
2001 Mar
Kinetic and mutagenic characterization of the chromosomally encoded Salmonella enterica AAC(6')-Iy aminoglycoside N-acetyltransferase.
2001 Mar 27
Management of corneal epithelial defects following laser in situ keratomileusis.
2001 Mar-Apr
Natural antibiotic susceptibility of recently established coryneform bacteria.
2001 May
[Functional characterization of a multiple-antibiotic resistant plasmid from clinical isolates of methicillin-resistant Staphylococcus aureus].
2001 May
Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II--tissue distribution.
2001 May
Inhibition of the HIV-1 rev-RRE complex formation by unfused aromatic cations.
2001 May
In vitro characteristics of tobramycin aerosol from ultrasonic and jet nebulizers.
2001 May
Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study.
2001 May
Epidemiologic Study of Pseudomonas aeruginosa in critical patients and reservoirs.
2001 May-Jun
A comparison of cortisporin and ciprofloxacin otic drops as prophylaxis against post-tympanostomy otorrhea.
2001 Nov 1
Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis.
2001 Oct
The treatment of cystic fibrosis--step by step.
2001 Oct
Effects of antibiotics on morphologic characteristics and migration of canine corneal epithelial cells in tissue culture.
2001 Oct
Bacillus cereus keratitis associated with contact lens wear.
2001 Oct
Efficacy and safety of aerosolized tobramycin in cystic fibrosis.
2001 Oct
Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization.
2001 Oct
Gene expression in Pseudomonas aeruginosa biofilms.
2001 Oct 25
The changing nature of aminoglycoside resistance mechanisms and prevalence of newly recognized resistance mechanisms in Turkey.
2001 Sep
Isolation and culture of airway epithelial cells from chronically infected human lungs.
2001 Sep
[Survey of the antibiotic sensitivity of Pseudomonas aeruginosa in France and the distribution of beta-lactam resistance mechanisms: the GERPB 1999 study].
2001 Sep
Treatment With tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa.
2001 Sep
Evaluating possible pharmacokinetic interactions between tobramycin, piperacillin, and a combination of piperacillin and tazobactam in patients with various degrees of renal impairment.
2001 Sep
Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting.
2001 Sep
Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.
2001 Sep 22
Aerosols and anti-infectious agents.
2001 Spring
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Tobramycin does not pass the gastro-intestinal tract, so for systemic use it can only be given intravenously or intramuscularly http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/063111s014lbl.pdf. Dosage is different for different infections. Ophthalmic route of administration is also possible, as indicated here http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails or for TOBREX http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050541s024lbl.pdf
KITABIS PAK is a co-packaging of tobramycin inhalation solution ampules with a PARI LC PLUS Reusable Nebulizer. Administer as follows: One single-use ampule (300 mg /5 mL) of tobramycin inhalation solution twice a day by oral inhalation in alternating periods of 28 days on drug, followed by 28 days off drug. The 300 mg/5mL dose of tobramycin inhalation solution is the same for all patients regardless of age or weight. The doses should be taken as close to 12 hours apart as possible; they should not be taken less than 6 hours apart.
Route of Administration: Respiratory
In Vitro Use Guide
Curator's Comment: Low dose tobramycin (4 ug/ml) as a single agent was bactericidal against only 16% of Pseudomonas aeruginosa isolates; however, 72% of isolates were killed with high-dose tobramycin (200 ug/ml).
High-dose tobramycin (200 ug/ml) killed 72% of Pseudomonas aeruginosa isolates
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:34:08 GMT 2023
Edited
by admin
on Fri Dec 15 15:34:08 GMT 2023
Record UNII
VZ8RRZ51VK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TOBRAMYCIN
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
TOBRAMYCIN [ORANGE BOOK]
Common Name English
TOBRASONE COMPONENT TOBRAMYCIN
Common Name English
TOBRAMYCIN [USP MONOGRAPH]
Common Name English
ZYLET COMPONENT TOBRAMYCIN
Common Name English
TOBRAMYCIN COMPONENT OF ZYLET
Common Name English
TOBRAMYCIN [EP MONOGRAPH]
Common Name English
TOBREX
Brand Name English
TOBRAMYCIN [JAN]
Common Name English
TOBRAMYCIN [HSDB]
Common Name English
tobramycin [INN]
Common Name English
NEBRAMYCIN VI
Common Name English
TOBRAMYCIN [MI]
Common Name English
TOBRADEX ST COMPONENT TOBRAMYCIN
Common Name English
AKTOB
Brand Name English
NEBRAMYCIN FACTOR 6
Common Name English
TOBRAMYCIN [VANDF]
Common Name English
47663
Code English
TOBRAMYCIN COMPONENT OF TOBRADEX
Common Name English
KITABIS PAK
Brand Name English
TOBRAMYCIN COMPONENT OF TOBRADEX ST
Common Name English
D-STREPTAMINE, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-.ALPHA.-D-RIBO-HEXOPYRANOSYL-(1->4))-2-DEOXY-
Common Name English
VANTOBRA
Brand Name English
O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-.ALPHA.-D-RIBO-HEXOPYRANOSYL-(1.ALPHA.6))-2-DEOXY-L-STREPTAMINE
Common Name English
TOBRAMYCIN COMPONENT OF TOBRASONE
Common Name English
TOBI PODHALER
Brand Name English
NSC-180514
Code English
TOBRAMYCIN [USAN]
Common Name English
TOBRAMYCIN [MART.]
Common Name English
TOBRAMYCIN [USP-RS]
Common Name English
Tobramycin [WHO-DD]
Common Name English
TOBI
Brand Name English
TOBRADEX COMPONENT TOBRAMYCIN
Common Name English
Classification Tree Code System Code
NDF-RT N0000007853
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
NCI_THESAURUS C2363
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
WHO-ATC S01AA12
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
WHO-VATC QJ01GB01
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
EU-Orphan Drug EU/3/06/366
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
FDA ORPHAN DRUG 84494
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
LIVERTOX NBK548505
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
WHO-VATC QS01AA12
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
FDA ORPHAN DRUG 271908
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
FDA ORPHAN DRUG 278009
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
CFR 21 CFR 862.3900
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
WHO-ATC J01GB01
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
NDF-RT N0000175477
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
FDA ORPHAN DRUG 281709
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
EMA ASSESSMENT REPORTS VANTOBRA (AUTHORIZED: CYSTIC FIBROSIS)
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
EMA ASSESSMENT REPORTS TOBI PODHALER (AUTHORIZED: CYSTIC FIBROSIS)
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
FDA ORPHAN DRUG 121098
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
Code System Code Type Description
NSC
180514
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
PRIMARY
CAS
32986-56-4
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
PRIMARY
EPA CompTox
DTXSID8023680
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
PRIMARY
LACTMED
Tobramycin
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
PRIMARY
NCI_THESAURUS
C62082
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
PRIMARY
RS_ITEM_NUM
1667508
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
PRIMARY
INN
2990
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
PRIMARY
CHEBI
73678
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
PRIMARY
PUBCHEM
36294
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
PRIMARY
FDA UNII
VZ8RRZ51VK
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
PRIMARY
EVMPD
SUB11134MIG
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
PRIMARY
MESH
D014031
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
PRIMARY
DAILYMED
VZ8RRZ51VK
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
PRIMARY
ECHA (EC/EINECS)
251-322-5
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
PRIMARY
ChEMBL
CHEMBL1747
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
PRIMARY
CHEBI
28864
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
PRIMARY
DRUG CENTRAL
2684
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
PRIMARY
RXCUI
10627
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
PRIMARY RxNorm
WIKIPEDIA
TOBRAMYCIN
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
PRIMARY
MERCK INDEX
m10917
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
PRIMARY Merck Index
HSDB
3259
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
PRIMARY
SMS_ID
100000091065
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
PRIMARY
DRUG BANK
DB00684
Created by admin on Fri Dec 15 15:34:08 GMT 2023 , Edited by admin on Fri Dec 15 15:34:08 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
BINDER->LIGAND
ROUTE OF ADMINISTRATION: INJECTION
BINDING
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MIC BIOLOGICAL ROUTE OF ADMINISTRATION: INJECTION

SUSCEPTIBILITY: RESISTANT

Biological Half-life PHARMACOKINETIC POPULATION: NEONATES ≥ 1200 GRAMS

Tmax PHARMACOKINETIC DOSAGE FORM: POWDER

ROUTE OF ADMINISTRATION: ORAL INHALATION

Volume of Distribution PHARMACOKINETIC ROUTE OF ADMINISTRATION: INJECTION

POPULATION: CHILDREN

Biological Half-life PHARMACOKINETIC POPULATION: INFANTS

Biological Half-life PHARMACOKINETIC POPULATION: CHILDREN

Volume of Distribution PHARMACOKINETIC ROUTE OF ADMINISTRATION: INJECTION

POPULATION: NEONATES

Volume of Distribution PHARMACOKINETIC ROUTE OF ADMINISTRATION: INJECTION

POPULATION: ADULTS

Biological Half-life PHARMACOKINETIC DOSAGE FORM: POWDER

ROUTE OF ADMINISTRATION: ORAL INHALATION

Biological Half-life PHARMACOKINETIC POPULATION: NEONATES ≤ 1200 GRAMS

MIC BIOLOGICAL PATHOGEN: LOW ORDER OF ACTIVITY AGAINST MOST GRAM-POSITIVE ORGANISMS INCLUDING S. PNEUMONIAE, S. PYOGENES, AND ENTEROCOCCI

SUSCEPTIBILITY: SUSCEPTIBLE

PATHOGEN: S. AUREUS, CITROBACTER spp., ENTEROBACTER spp., E. COLI, KLEBSIELLA spp., MORGANELLA MORGANII, P. AEURUGINOSA, P. MIRABILIS, PROTEUS VULGARIS, PROVIDENCIA spp., SERRATIA spp.

ROUTE OF ADMINISTRATION: INJECTION

Tmax PHARMACOKINETIC ROUTE OF ADMINISTRATION: IM

Volume of Distribution PHARMACOKINETIC ROUTE OF ADMINISTRATION: INJECTION

POPULATION: INFANTS

Volume of Distribution PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL INHALATION

DOSAGE FORM: POWDER

POPULATION: TYPICAL CYSTIC FIBROSIS PATIENTS

Biological Half-life PHARMACOKINETIC POPULATION: ADULTS WITH IMPAIRED RENAL FUNCTION

Tmax PHARMACOKINETIC ROUTE OF ADMINISTRATION: IIV

Biological Half-life PHARMACOKINETIC DOSAGE FORM: SOLUTION

ROUTE OF ADMINISTRATION: ORAL INHALATION

Biological Half-life PHARMACOKINETIC POPULATION: ADOLESCENTS

MIC BIOLOGICAL SUSCEPTIBILITY: INTERMEDIATE

ROUTE OF ADMINISTRATION: INJECTION

Biological Half-life PHARMACOKINETIC ROUTE OF ADMINISTRATION: IV

POPULATION: ADULTS

Volume of Distribution PHARMACOKINETIC ROUTE OF ADMINISTRATION: INJECTION

POPULATION: ADOLESCENTS